ResultsIQ

ResultsIQ › Latest results › Alivus Life Sciences Limited

Alivus Life Sciences Limited Q1 FY27 results deck summary

NSE: ALIVUS · BSE: 543322

Results deck of 30 Jul 2026, summarised by AI from the filing.

Alivus Q1 FY27 revenue ₹6,404 mn, up 6.4% YoY, with FY27 guidance of 10-12% revenue growth and 30-32% EBITDA margin.

Key takeaways

  1. FY27 guidance Management guides revenue growth of 10% - 12% in FY27 and EBITDA margins in the 30%–32% range.
  2. Growth driver Non-GPL business growth anchored by demand across geographies and new product launches.

Original filing on BSE

Alivus Life Sciences Limited Q1 FY27 results

As filed: Revenue ₹640 cr (+6% year on year), EBITDA ₹212 cr (+23% year on year), PAT ₹160 cr (+31% year on year), EBITDA margin 33.1% (+449 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹689 cr (+6% year on year), EBITDA ₹215 cr (+8% year on year), PAT ₹163 cr (+15% year on year), EBITDA margin 31.1% (+67 bps). Score 48 of 100, In line with trend. EBITDA margin rose 67 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −1.7% in 29 days (Nifty 500: −0.1%).
  • Q3 FY26: Revenue ₹673 cr (+5% year on year), EBITDA ₹231 cr (+22% year on year), PAT ₹150 cr (+21% year on year), EBITDA margin 34.4% (+477 bps). Score 59 of 100, In line with trend. EBITDA margin rose 477 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +11.1% in 29 days (Nifty 500: +2.5%).
  • Q2 FY26: Revenue ₹588 cr, EBITDA ₹178 cr, PAT ₹130 cr, EBITDA margin 30.3%. Not scored. No result for the same quarter last year. Share price after the results: −0.8% in 29 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹602 cr, EBITDA ₹172 cr, PAT ₹122 cr, EBITDA margin 28.6%. Not scored. No result for the same quarter last year. Share price after the results: −5.6% in 28 days (Nifty 500: −0.9%).
  • Q4 FY25: Revenue ₹650 cr, EBITDA ₹198 cr, PAT ₹142 cr, EBITDA margin 30.5%. Not scored. No result for the same quarter last year. Share price after the results: −15.9% in 29 days (Nifty 500: +0.5%).
  • Q3 FY25: Revenue ₹642 cr, EBITDA ₹190 cr, PAT ₹137 cr, EBITDA margin 29.6%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Alivus Life Sciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.